Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aridis Pharmaceuticals Inc (NQ: ARDS )

0.1846 +0.0035 (+1.93%)
Streaming Delayed Price Updated: 3:59 PM EDT, May 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Aridis Pharmaceuticals Inc

< Previous 1 2 3 4 5 Next >
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
(Updated) Aridis Pharmaceuticals Receives Equity Investment from the Cystic Fibrosis Foundation
From Aridis Pharmaceuticals, Inc.
Via GlobeNewswire
Aridis Pharmaceuticals Receives Equity Investment from the Cystic Fibrosis Foundation
From Aridis Pharmaceuticals, Inc.
Via GlobeNewswire
Aridis Pharmaceuticals Return On Capital Employed Overview
  
Via Benzinga
Aridis' Inhaled Pan-Coronavirus Antibody Cocktail Shows Encouraging Preclinical Action
 
Via Benzinga
Aridis Signs Exclusive Terms to Secure Worldwide Commercial Licenses for Pan-Ebola and Pan-Marburg Monoclonal Antibody Programs from Mapp Biopharmaceutical
From Aridis Pharmaceuticals, Inc.
Via GlobeNewswire
Aridis Announces a Key Milestone of Closing of Patient Enrollment in the Phase 2a Study of AR-501 in Cystic Fibrosis Patients
From Aridis Pharmaceuticals, Inc.
Via GlobeNewswire
Aridis to Participate in Key Opinion Leader Discussion on Immunotherapy for Infectious Diseases
From Aridis Pharmaceuticals, Inc.
Via GlobeNewswire
Aridis Pharmaceuticals Announces Third Quarter 2022 Financial Results and Business Update
From Aridis Pharmaceuticals, Inc.
Via GlobeNewswire
A Novel Immunotherapy That Could Bring Hope To Millions Of Sepsis Patients Received MultiCountry Clearance For Expanded Clinical Trial
Enlivex Therapeutics Ltd. (NASDAQ: ENLV) announced that Israel, Spain and Greece have cleared amendments to the company’s Phase II trial protocol that will allow the study to enroll more patients. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Acumen Pharmaceuticals (NASDAQ:ABOS) shares increased by 80.8% to $8.5 during Wednesday's pre-market session. The company's market cap stands at $344.2 million. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers 9 Meters Biopharma (NASDAQ:NMTR) stock moved upwards by 22.8% to $0.25 during Tuesday's pre-market session. The company's market cap stands at $65.8 million. 
Via Benzinga
Why Kiora Pharmaceuticals Is Trading Lower By Around 22%; Here Are 26 Stocks Moving Premarket
Gainers 9 Meters Biopharma, Inc. (NASDAQ: NMTR) rose 31.4% to $0.2720 in pre-market trading after the company disclosed final results from Phase 2 VIBRANT study, End-of-Phase 2 meeting with the FDA for... 
Via Benzinga
Why Aridis Pharmaceuticals Shares Plunged Around 30%; Here Are 81 Biggest Movers From Yesterday
Gainers 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Aridis Pharmaceuticals (NASDAQ:ARDS) shares moved upwards by 20.1% to $1.79 during Wednesday's after-market session. The market value of their outstanding shares is at $31.6 million. 
Via Benzinga
Why Amazon Shares Traded Lower; Here Are 74 Biggest Movers From Yesterday
Gainers Bright Minds Biosciences Inc. (NASDAQ: DRUG) shares jumped 72.8% to close at $2.16 on Monday as the stock continued to see momentum despite the company last week announcing it is not aware of... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
  
Via Benzinga
Why MSP Recovery Is Trading Higher By Over 21%, Here Are 61 Stocks Moving In Monday's Mid-Day Session
 Losers 
Via Benzinga
Recap: Aridis Pharmaceuticals Q2 Earnings
  Aridis Pharmaceuticals (NASDAQ:ARDS) reported its Q2 earnings results on Tuesday, August 16, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Aridis... 
Via Benzinga
Biotech Daily: Cancer Causing Impurities In Merck's Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans For COVID-19 Treatment, Aethlon's Monkeypox Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
This Communication Services Stock Jumped 149%; Here Are 90 Biggest Movers From Friday
Gainers Getty Images Holdings, Inc. (NYSE: GETY) shares climbed 149.1% to close at $26.15 on Friday following its merger with special-purpose acquisition company (SPAC) CC Neuberger Principal Holdings... 
Via Benzinga
This Healthcare Stock Tumbled 43%; Here Are 88 Biggest Movers From Yesterday
Gainers Athersys, Inc. (NASDAQ: ATHX) climbed 71.1% to close at $0.3250 on Thursday after gaining 10% on Wednesday. Athersys is expected to release its Q2 financial results on Thursday, August 11,... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
  
Via Benzinga
Why Shares of Solar Companies Are Trading Higher? 64 Stocks Moving In Thursday's Mid-Day Session
Gainers 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Good morning, investor! We're starting off this week of trading with a look at the biggest pre-market stock movers for Monday! 
Via InvestorPlace
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
RedChip Interviews Aridis Pharmaceuticals' CEO Vu Truong
ORLANDO, FL / ACCESSWIRE / June 30, 2022 / RedChip Companies will air a new C-Level interview with Aridis Pharmaceuticals (NASDAQ:ARDS) on The RedChip Money Report® on Bloomberg TV, this Saturday, July... 
From RedChip
Via AccessWire
Exposures COVID-19
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
91 Biggest Movers From Friday
Gainers RISE Education Cayman Ltd (NYSE: REDU) shares jumped 138.5% to settle at $3.41 on Friday. RISE Education announced expected timing for the completion of the merger with Dada Auto. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.